TAVR for low-risk severe aortic stenosis: is this the end of surgical valve replacement?

TAVR for low-risk severe aortic stenosis: is this the end of surgical valve replacement?
BMJ Evidence-Based Medicine 1 November 2019. doi: 10.1136/bmjebm-2019-111259 [NHS OpenAthens required]

• New trials, PARTNER 3 and Evolut Low Risk, showed promising results for transcatheter aortic valve replacement for low-risk surgical patients with severe aortic stenosis. However, there remain caveats to its use in this population in clinical practice.